|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
L01BC05
|
|
gptkbp:CASNumber
|
95058-81-4
|
|
gptkbp:contraindication
|
hypersensitivity to gemcitabine
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
42-94 minutes
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
lyophilized powder for injection
|
|
gptkbp:genericName
|
gemcitabine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gemzar
|
|
gptkbp:KEGGID
|
D00564
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antiviral drug
antineoplastic agent
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB00441
54725
60750
CHEMBL1633
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
vomiting
rash
neutropenia
|
|
gptkbp:synonym
|
gptkb:2',2'-difluorodeoxycytidine
dFdC
|
|
gptkbp:UNII
|
G3UV8Q2FS5
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
pancreatic cancer
bladder cancer
|
|
gptkbp:bfsParent
|
gptkb:Lilly_Oncology
gptkb:Gemcitabine
|
|
gptkbp:bfsLayer
|
7
|